Engraftment of gene-marked hematopoietic progenitors in myeloma patients after transplant of autologous long-term marrow cultures.
We conducted a phase I hematopoietic stem cell (HSC) gene-marking trial in patients undergoing autologous blood or marrow stem cell transplant for the treatment of multiple myeloma. Between 500 and 1000 ml of bone marrow was harvested from each of 14 myeloma patients and 1 syngeneic donor. A mean of 3.3x10(9) cells per patient were plated in 20 to 50 long-term marrow culture (LTMC) flasks and maintained for 3 weeks. LTMCs were exposed on days 8 and 15 to clinical-grade neo(r)-containing retrovirus supernatant (G1Na). A mean of 8.23x10(8) day-21 LTMC cells containing 5.2x10(4) gene-marked granulocyte-macrophage progenitor cells (CFU-GM) were infused along with an unmanipulated peripheral blood stem cell graft into each patient after myeloablative therapy. Proviral DNA was detected in 71% of 68 tested blood and bone marrow samples and 150 of 2936 (5.1%) CFU-GM derived from patient bone marrow samples after transplant. The proportion of proviral DNA-positive CFU-GM declined from a mean of 9.8% at 3 months to a mean of 2.3% at 24 months postinfusion. Southern blots of 26 marrow and blood samples were negative. Semiquantitative PCR analysis indicated that gene transfer was achieved in 0.01-1% of total bone marrow and blood mononuclear cells (MNCs). Proviral DNA was also observed in EBV-transformed B lymphocytes, in CD34+ -enriched bone marrow cells, and in CFUs derived from the latter progenitors. Gene-modified cells were detected by PCR in peripheral blood and bone marrow for 24 months after infusion of LTMC cells. Sensitivity and specificity of the PCR assays were independently validated in four laboratories. Our data confirm that HSCs may be successfully transduced in stromal based culture systems. The major obstacle to therapeutic application of this approach remains the overall low level of genetically modified cells among the total hematopoietic cell pool in vivo.
Stewart
A K
AK
Department of Medicine, The Toronto Hospital, Ontario, Canada. k.stewart@utoronto.ca
Sutherland
D R
DR
Nanji
S
S
Zhao
Y
Y
Lutzko
C
C
Nayar
R
R
Peck
B
B
Ruedy
C
C
McGarrity
G
G
Tisdale
J
J
Dubé
I D
ID
D001854:Bone Marrow Cells / Q000473:pathology / Q000502:physiology; D016026:Bone Marrow Transplantation; D002478:Cells, Cultured; D004279:DNA, Viral / Q000032:analysis; D018014:Gene Transfer Techniques; D005819:Genetic Markers; D005822:Genetic Vectors; D018380:Hematopoietic Stem Cell Transplantation; D006412:Hematopoietic Stem Cells / Q000473:pathology / Q000502:physiology*; D006801:Humans; D019868:Kanamycin Kinase / Q000235:genetics; D009101:Multiple Myeloma / Q000628:therapy*; D016133:Polymerase Chain Reaction / Q000379:methods; D011533:Proviruses; D012190:Retroviridae / Q000235:genetics; D014182:Transplantation, Autologous
D004279:DNA, Viral; D005819:Genetic Markers; D019868:Kanamycin Kinase